In the BioHarmony Drug Report Database
Omalizumab
Xolair (omalizumab) is an antibody pharmaceutical. Omalizumab was first approved as Xolair on 2003-06-20. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma and urticaria. The pharmaceutical is active against Immunoglobulin heavy constant epsilon.
Trade Name
|
Xolair |
|---|---|
Common Name
|
omalizumab |
ChEMBL ID
|
CHEMBL1201589 |
Indication
|
asthma, urticaria |
Drug Class
|
Monoclonal antibodies: humanized, immunomodulating |
Image (chem structure or protein)
